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in vivo
Hemi Dimant1, Suneil K Kalia1,2†, Lorraine V Kalia1,3†, Liya N Zhu1, Laura Kibuuka1, Darius Ebrahimi-Fakhari1,4,
Nikolaus R McFarland1,5, Zhanyun Fan1, Bradley T Hyman1 and Pamela J McLean1,6*Abstract
Background: Rat models of Parkinson’s disease are widely used to elucidate the mechanisms underlying disease
etiology or to investigate therapeutic approaches. Models were developed using toxins such as MPTP or 6-OHDA to
specifically target dopaminergic neurons resulting in acute neuronal loss in the substantia nigra or by using viral
vectors to induce the specific and gradual expression of alpha synuclein in the substantia nigra. The detection of
alpha- synuclein oligomers, the presumed toxic species, in these models and others has been possible using only
indirect biochemical approaches to date. Here we coinjected AAVs encoding alpha-synuclein fused to the N- or
C-terminal half of VenusYFP in rat substantia nigra pars compacta and describe for the first time a novel viral vector
rodent model with the unique ability to directly detect and track alpha synuclein oligomers ex vivo and in vivo.
Results: Viral coinjection resulted in widespread VenusYFP signal within the nigrostriatal pathway, including cell
bodies in the substantia nigra and synaptic accumulation in striatal terminals, suggestive of in vivo alpha-synuclein
oligomers formation. Transduced rats showed alpha-synuclein induced dopaminergic neuron loss in the substantia
nigra, the appearance of dystrophic neurites, and gliosis in the striatum. Moreover, we have applied in vivo imaging
techniques in the living mouse to directly image alpha-synuclein oligomers in the cortex.
Conclusion: We have developed a unique animal model that provides a tool for the Parkinson’s disease research
community with which to directly detect alpha- synuclein oligomers in vivo and screen therapeutic approaches
targeting alpha-synuclein oligomers.
Keywords: Parkinson’s disease, Alpha synuclein, Oligomers, Animal model, Live imagingBackground
Alpha synuclein (α-syn) aggregation has been closely
linked to Parkinson’s disease (PD) etiology. Lewy Bodies,
the pathological hallmark of PD are enriched with alpha
synuclein fibrils [1,2] and point mutations and gene
multiplications of the SNCA gene, which are associated
with increased α-syn accumulation, result in familial PD
[3-5]. Genome wide association studies have also dem-
onstrated that single nucleotide polymorphisms in the
SNCA loci may be a risk factor for idiopathic PD
(Edwards 2010). Although the exact mechanism of α-syn* Correspondence: mclean.pamela@mayo.edu
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reproduction in any medium, provided the orinduced toxicity remains unknown, recent observations
allude to soluble α-syn oligomers being neurotoxic [6-9].
Rat models of PD have been developed based on the
putative link between alpha synuclein and PD. First
generation PD rat models employed neurotoxins such as
6-OHDA (6-hyroxydopamine) or MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) which acutely degen-
erate dopaminergic (DA) neurons in the substanatia
nigra (SN), but do not result in significant α-syn path-
ology [10]. Second generation models use viral vectors
to target α-syn expression in the SN, resulting in a more
gradual expression of α-syn with accompanying dopa-
minergic cell loss, which more closely resembles the
chronic pathology of PD [11-14]. In these models and
others, the detection of α-syn oligomers is based upon
indirect approaches and biochemical techniques, but
none offers direct detection of α-syn oligomers in vivo.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PD using bimolecular protein complementation assay
(PCA) to enable the direct detection and visualization of
α-syn oligomers along the nigrostriatal pathway. PCAs
have been successfully applied to image protein-protein
interactions in vivo based on a chemiluminescence signal
from protein-luciferase conjugates, typically by trans-
planting immortalized cells expressing the protein-protein
complementation pairs into organs of living mice [15].
While supporting the feasibility of complementation
in vivo, none of the PCAs described to date have directly
introduced each protein fragment separately and noneFigure 1 Detection of alpha synuclein oligomerization in the SN using
AAV-V1S (a, upper) and AAV-SV2 (a, lower) constructs designed for the PC
AAV-SV2 were mounted onto slides and directly imaged under a fluorescen
with both AAV-V1S and AAV-SV2 and is localized to the SN (b, middle pan
and neurites (b, lower panel). No fluorescence is observed in the non-inje
AAV-V1S or AAV-SV2 (b, upper panel). Scale bar 500 μm and 50 μm in mihave done so using fluorescence as an output rather than
chemiluminescence.
The PCA approach, successfully applied in our labora-
tory to detect and image α-syn oligomers in vitro
[7,8,16-18], is demonstrated here in vivo by viral medi-
ated expression of human α-syn fused to either the N-
or C- terminus half of venusYFP. Formation of fluores-
cently labeled α-syn oligomers is directly visualized
along the nigrostriatal pathway ex-vivo in rat brain and
in cortical neurons in vivo in a living mouse brain. Our
novel approach for the direct detection of α-syn oligo-
mers in vivo provides a powerful tool to study the roleprotein complementation assay. Schematic representation of the
A. Coronal sections from the SN of rats injected with AAV-V1S and
ce microscope. Reconstituted VenusYFP is visible in animals injected
el). VenusYFP is visible in the SNpc and the SNpr within cell bodies
cted contralateral side as well as in control animals injected with either
ddle and lower panels respectively.
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http://www.actaneurocomms.org/content/1/1/6of α-syn oligomers in PD and to explore therapeutic ap-
proaches targeting α-syn oligomerization.
Results
Direct detection of alpha synuclein oligomers in the rat
nigrostriatal pathway
In this study we developed two AAVs expressing human
WT α-syn fused with either the N-terminus or C-
terminus half of venusYFP protein (AAV-Venus1Syn and
AAV-SynVenus2, referred to hereon out as V1S and
SV2). AAVs were directly co-injected into the substantia
nigra pars compacta (SNpc) of Sprague Dawley rats.
Two additional control groups of animals were injected
with either V1S virus or SV2 virus to exclude the possi-
bility of non-specific fluorescence from one half of the
venusYFP protein. At eight weeks post viral injection
venusYFP fluorescence was clearly observable in the SN
of animals injected with V1S + SV2, including the SN pars
compacta and SN pars reticulata (Figure 1). Venus fluores-
cence was visible in cell bodies and in neuronal projections
which, to some extent, could be traced to their respective
neurons (Figure 1, 3 arrows). No fluorescence was visible
in the non-injected contralateral side. The reconstitution
of venusYFP fluorescence in vivo demonstrates the suc-
cessful complementation of venusYFP halves via the for-
mation of α-syn oligomers. Notably, in control animals
injected with either V1S or SV2 alone we detected no
venusYFP fluorescence in the injected (ipsilateral) side,Figure 2 Alpha synuclein associated neurotoxicity in the SN. Unbiased
across the SN was performed using DAB. Cytotoxicity is determined by ext
(right, asterisk) vs. contralateral (left) (a). A 43% lesion was measured in rats
51% lesion was measured in rats injected only with SV2 (n = 7, p < 0.0001),
measured in the SNpc, was also noticeable in the striatum (c). In the contr
lesion was measured (n = 4) (b). Representative image are displayed. Scaledemonstrating that the fragmented venus protein does not
have any background fluorescence (Figure 1).
Alpha synuclein associated toxicity
To determine if the overexpression of α-syn oligomers
the SN results in dopaminergic cell death we examined
neuronal viability 8 weeks after viral injection. Coronal
sections from the SN were immunostained for tyrosine
hydroxylase (TH) and immunopositive cells visualized
by DAB were counted using unbiased stereology both
ipsilaterally and contralaterally (Figure 2a). The ratio of
cells ipsilateral to contralateral was calculated and the
extent of lesion was determined. Groups of animals
injected with AAV8-V1S + AAV8-SV2 (n = 8) as well as
control groups injected with AAV8-venus (n = 4) and
AAV8-SV2 (n = 7) alone were included in the analyses.
Stereological analyses revealed 43% TH cell loss in ani-
mals co-injected with V1S + SV2 (Figure 2b). As expected
a significant 51% TH cell loss was observed in the group
of animals expressing only SV2, where oligomers are
presumed to form but are not detectable (Figure 2b). A
reduction in TH staining is also noticeable in the stri-
atum, further conforming lesion formation (Figure 2c).
In control animals expressing full length venus protein
we observed an insignificant 15% TH cell loss consistent
with the absence of a lesion (Figure 2b). These data
demonstrates an α-syn induced toxicity resulting in
neuronal cell loss.stereological analysis of TH immunopositive cells in coronal sections
ent of TH lesion as measured by the ratio of TH positive cells ipsilateral
injected with both AAV-V1S and AAV-SV2 (n = 8, p < 0.0001) and a
both significantly lower than a non-lesion value of one (b). The lesion,
ol group injected with full-length venusYFP a non-significant 15%
bar 500 μm and 100 μm (zoomed-in images) in a and 500 μm in c.
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striatum
The SN projects to and receives input from the striatum
along the nigrostraital pathway. To determine if α-syn
oligomers could also be detected in the striatum, coronal
sections of rats injected with AAV8-V1S and AAV8-SV2
as well as from rats injected with AAV8-venus were
mounted onto slides and directly imaged for fluorescence.
Ipsilateral venusYFP fluorescence was visible in the stri-
atum of animals injected with V1S + SV2, demonstrating
the direct detection of α-syn oligomers in the striatum
and confirming successful targeting of the viral injection
(Figure 3a). No venusYFP fluorescence was detected in
the contralateral side (Figure 3a). VenusYFP fluorescence
was visible only in neuronal termini with no evidence of
striatal cell body staining (Figure 3), arguing against retro-
grade transport of virus to the striatum. Of note, the
pattern of venusYFP fluorescence in the striatum isFigure 3 Detection of alpha synuclein oligomers in the striatum. The
AAV-SV2 in the SN were imaged for the presence of venusYFP fluorescence
imaged under fluorescence microscope. VenusYFP is directly detected and
fluorescence is detected contralateral (a). VenusYFP fluorescence is also de
fluorescence pattern is detected only in the striatum of animals injected w
injected with full length venusYFP (upper panel), suggestive for a possible
images are displayed. Scale bar 500 μm.distinctive to that observed in the SN. Venus fluorescence
in the striatum of animals co-injected with V1S and SV2 is
observed as multiple puncta (Figures 3a 1 and 2), which is
not observed in the striatum of control animals injected
with AAV8-venus (Figure 3b). Closer examination at
higher magnification reveals beaded and dystrophic
axons in animals expressing V1S and SV2 compared to
healthy appearing axons in animals expressing full
length venusYFP (Figure 4a), consistent with that
reported in viral vector models [12] overexpressing α-
syn. To determine if the observed α−syn oligomers rep-
resented insoluble aggregates we performed Proteinase
K (PK) digestion. Following PK treatment, venusYFP
fluorescence was completely absent, including puncta and
neurites. α-Syn immunostaining using the antibody 4B12
was also decreased following PK treatment, suggesting the
soluble nature of α-syn oligomers expressed in this model
(Figure 4b).neuronal projections in the striatum of rats injected with AAV-V1S and
. Coronal sections from the striatum of rats injected into the SN were
localized to the striatum in animals injected with V1S and SV2, no
tected in the striatum of rats injected with AAV-venus (b). Punctate
ith V1S and SV2 compared to the diffuse staining observed in animals
accumulation of alpha synuclein within the striatum. Representative
V1S SV2 venusa
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Figure 4 Alpha synuclein associated pathology in the striatum. Lower and higher magnification images of axons in the striatum of animals
expressing V1S SV2 or full length venusYFP (a). Beaded dystrophic axons are observed only in animals expressing α-syn compared to animals
expressing venusYFP showing neurites with a normal appearance (a). VenusYFP fluorescence and α-syn immunostaining were both diminished
following PK treatment suggestive to the soluble nature of visualized oligomers (b). Scale bar 200 μm upper panel a and 50 μm lower panel a
and panel b.
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Neuroinflammation plays an important role in the
pathophysiology of PD [19] with studies linking striatal
neuroinflammation to neurotoxicity and disease progres-
sion as a result of α-syn aggregation [20,21]. Striatal
sections of injected animals were analyzed to determine
whether the expression of α-syn oligomers results in a
concomitant inflammatory response (Figure 5a). Animals
injected with V1S + SV2 (n = 8) or full-length venusYFP
(n = 4) were immunostained for GFAP, a marker of
astrocyte activation (Figure 5b), and Iba1 a microglial
marker (Figure 5c). High resolution image analyses re-
vealed a significant elevation in the median expression
of GFAP ipsilateral compared to the contralateral striatum
of the V1S + SV2 group. In control animals expressing full
length venusYFP, GFAP expression remained unchanged
as reflected by a ratio value of 1 (Figure 5d). No difference
was measured in the ratio of Iba1 expression with either
the V1S + SV2 group or the venusYFP group (Figure 5e).
The increase in GFAP expression in animals expressing α-
syn suggests an α-syn associated gliosis in the striatum.
In vivo imaging of alpha synuclein oligomers in the living
mouse
The data thus far demonstrate our ability to detect α-syn
oligomers along the nigrostraital pathway ex-vivo using
a novel in vivo complementation assay of α-syn. Next we
examined whether α-syn oligomers are detectable in the
brain of a living animal using two-photon microscopy
which, through deeper tissue penetrance, allows imaging
of an intact brain up to 300 μm deep. C57bl6 mice wereco-injected with AAV8-V1S + AAV8-SV2 into layer 2–3
of the cortex. After 4 weeks a craniotomy was performed
to expose the brain and install a cranial window to allow
imaging of the intact brain in the living animal [22].
Under low magnification and using an epifluorescence
light source, venusYFP fluorescence could be clearly
detected at the injection site in mice co-injected with
V1S and SV2 (Figure 6a). Deep tissue imaging at higher
magnification using two photon microscopy revealed
venusYFP fluorescence along neurites (Figure 6b) at a
depth of 160 μm (Figure 6c) and in cell bodies at a depth
of up to 250 μm (Figure 6d).
Conclusions
We herein present a novel in vivo protein complementa-
tion approach to directly detect α-syn oligomers in ro-
dent brain. We demonstrate the successful targeted
delivery of two AAVs into the substantia nigra (SN) and
the direct ex-vivo imaging of α-syn oligomers in the
nigrostriatal pathway including the SN and the striatum.
We demonstrate α-syn induced toxicity as measured by
a reduction in TH-positive neurons in the SN as well as
gliosis (astrocytosis) in the striatum. We also demon-
strate that multi-photon imaging can be applied to
specifically image α-syn oligomers in the brains of living
mice.
In recent years studies have shown that α-syn oligo-
mers play a key role in PD etiology, shifting the blame
from mature α-syn fibrils, such as in Lewy bodies, to sol-
uble oligomers [6,23,24]. Previous studies conducted in
our laboratory have shown the applicability of PCA to
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Figure 5 Neuroinflammation in the striatum. Striatal coronal sections were immunostained for GFAP expression (a). Mean intensity
quantification of GFAP (b) and Iba1 (c) staining was conducted in the striatum ipsilateral over contralateral, in the V1S and SV2 or venusYFP
group. Data analysis revealed a 9% elevation in the ratio of GFAP expression ipsilateral over contralateral in animals injected with V1S and SV2
(n = 8, p < 0.005) compared to animals injected with full-length venusYFP (n = 4) showing no changes in the level of GFAP expression ipsilateral
vs. contralateral (d). Iba1 expression ratio in the V1S SV2 group was similar to the control group (e). Representative images are displayed. Scale
bar 500 μm and 20 μm in A, 200 μm in B and C.
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means to further dissect the role of α-syn oligomers in
PD [7,8,16-18]. Here we show for the first time the
advantage of this powerful technique to detect and
visualize α-syn oligomerization in vivo.
AAVs (V1S + SV2) were injected into the SN of Sprague
Dawley rats and incubated for a period of 8 weeks, at the
end of which histological analysis was conducted to
validate the detection of α-syn oligomers. VenusYFP fluor-
escence is detected in the SN including the pars compacta
(SNpc) and pars reticulata (SNpr) and to some extent in
the ventral tegmental area (VTA). This demonstrates the
direct delivery and expression of 2 viruses which results in
in vivo α-syn oligomer formation. Control animals
injected with only one of the viruses, either V1S or SV2,
did not exhibit any fluorescence in the injection site, even
though they presumably form oligomers as well [25].
Looking at neurons in the SN, we detect fluorescence in
neurites, neuronal cell bodies, and the nucleus, as sug-
gested by our inability to delineate nuclei [26]. Quantita-
tion of tyrosine hydroxylase immunopositive neurons inthe SN revealed an average lesion of 45% in animals ex-
pressing α-syn regardless of whether we could directly
detect oligomers via fluorescence or not, in accordance
with previously reported α-syn-induced lesions in viral
vector rat models [11-14,27]. These results indicate that
bimolecular fluorescent PCA with α-syn-Venus con-
structs does not artificially enhance α-syn toxicity, but
rather is strictly an assay for α-syn oligomer formation.
Furthermore, in animals expressing only full length
venusYFP, no significant TH cell death was detected,
demonstrating that neither the expression of full length
venusYFP nor the injection procedure itself promotes a
lesion. The ability to directly detect α-syn oligomers
in vivo offers a powerful tool to elucidate the molecular
mechanisms of α-syn mediated neurotoxicity and to
examine α-syn based therapies.
Dopaminergic neurons project to the striatum along
the nigrostraital pathway. Accordingly, we detect α-syn
oligomers in the striatum of rats injected in the SN, with
venusYFP fluorescence. This result demonstrates our
ability to detect and visualize α-syn oligomers along the
ab
c
d
Figure 6 In vivo imaging of alpha synuclein oligomers. Mice
injected intra-cortically with V1S and SV2 were installed with a
cranial window and imaged to visualize alpha synuclein
oligomerization in vivo. VenusYFP is visualized in the cortex and is
localized to the injection site, demonstrating successful venusYFP
complementation in vivo (a, arrow). Using two-photon microscopy
venusYFP fluorescence is imaged showing neurites at 180 μm (b,
green = venus, red = blood vessels) and cell bodies at 210 μm (d).
Higher magnification images reveal clear venusYFP fluorescence in
dendrites (c) and in dendritic spines (c, arrows). Scale bar 50 μm.
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targeting of the AAVs to neurons in the SN. Interest-
ingly, in the striatum of rats expressing α-syn we ob-
served distinct punctate fluorescence and dystrophic
axons, compared to the diffuse venusYFP fluorescence
and the healthy appearing axons observed in control
animals expressing only venusYFP. The punctate stain-
ing, observed only in the striatum of α-syn expressing
rats, was suggestive of α-syn aggregation, an intriguing
observation in light of recent evidence demonstratingthe synaptic localization of small α-syn aggregates in
DLB patients, linking α-syn aggregation to synaptic
pathology [28]. Proteinase K (PK) treatment reduced
venusYFP fluorescence in the striatum including puncta
and axons. α-Syn staining was likewise markedly de-
creased following PK treatment suggesting that α-syn
accumulation in the striatum represent soluble α-syn
oligomers.
Indeed this finding, taken together with accumulating
evidence implicating α-syn in disease progression via a
non-cell-autonomous neuroinflammatory process [29-31],
led us to investigate whether inflammation occurs con-
comitantly with the aggregation of α-syn in the striatum
and the presence of dystrophic neurites. Iba1 immuno-
staining showed no difference in microglial activation in
response to V1S + SV2 expression or venusYFP control.
However, GFAP analysis showed a small but significant
elevation in GFAP expression ipsilateral in the V1S +
SV2 group compared to that in control animals express-
ing only venusYFP. In accordance with our observation,
asctrocytic gliosis is commonly reported in rodents
models of α-synucleinopathies [32].
The uniquely designed PCA presented here has the
advantage to detect and visualize α-syn oligomerization
in post mortem tissue with minimal tissue processing, but
could potentially be utilized to monitor the formation of
α-syn oligomers over time in the brain of a living animal
using two-photon microscopy. Recent advances in two-
photon microscopy have enabled in vivo visualization of
protein aggregation and neurodegeneration in the brain of
an Alzheimer’s disease mouse model [22,33,34] and pro-
tein degradation in the brain of a PD animal model
[35-37]. Here, using two-photon microscopy, we demon-
strate the ability to image and detect α-syn oligomers
in vivo. High-resolution images showed venusYFP fluores-
cence in neuronal cell bodies and axons, in agreement
with a previous report examining cellular localization of
GFP-tagged α-syn using two-photon microscopy [35,36].
We have also imaged α-syn oligomers in dendrites and
dendritic spines, although we cannot rule out the possibil-
ity that the presence of a-syn in dendritic spines is an
artifact of overexpression. Nonetheless, although α-syn is
a pre-synaptic protein, our ability to image α-syn in the
synapse may provide insight into the effects of α-syn on
dendritic spines, which have been shown to degenerate in
DLB patients [28] and thus may play a role in disease pro-
gression through trans-synaptic mechanisms. It is import-
ant to emphasize that multi-photon imaging of neurons in
the brain of a living animal bestows the ability to perform
longitudinal studies on individual neurons which, coupled
with our ability to directly detect α-syn oligomers using
fluorescence, offers a powerful tool with which to monitor
α-syn aggregation and examine its direct effect on neu-
rons over time.
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http://www.actaneurocomms.org/content/1/1/6Taken together, we present here a unique animal
model to detect and monitor α-syn oligomer formation
in the brain of rodents. Our animal model will give re-
searchers the opportunity to better understand α-syn
associated pathogenesis specifically in the context of α-
syn oligomers in vivo but also offers great therapeutic
screening potential for therapeutic agents that target α-
syn oligomers.
Methods
Virus preparation
The viral vectors pAAV-CBA-VENUS1-SYNUCLEIN-
WPRE (V1S) and pAAV-CBA-SYNUCLEIN-VENUS2-
WPRE (SV2) were constructed by inserting the human
SNCA gene, fused to either the N-terminus half of
venusYFP (V1S) or the C-terminus half of venusYFP (SV2),
into the EcoRV and NheI sites of the pAAV-CBA-WPRE
vector [8]. pAAV-CBA-VenusYFP-WPRE was constructed
by inserting the venusYFP gene into the XhoI and NheI
sites of pAAV-CBA-WPRE vector. AAV serotype 8 was
produced by the Harvard Gene Therapy Initiative as
previously described [38].
Injections
Sprague Dawley rats (300–350 gram) were anesthetized
with intraperitoneal injection of ketamine/xylazine and
placed in a stereotaxic frame. The surgical site was
shaved and sterilized with betadine prior to making a
2 cm incision along the midline. The scalp was exposed
and a unilateral injection targeting the SN was preformed
at coordinates AP −5.2, ML −2 and DV −7.4 with bregma
as a point of reference. For each animal, a total volume of
2 μl of virus was injected at a rate of 0.2 μl/min using a
microinjection pump and 10 μl Hamilton syringe with a
30-gauge needle. For V1S + SV2 group 1 μl of AAV8- V1S
(8.3•1012 viral genome/ml) and 1 μl of AAV8-SV2 (8.7•1012
viral genome/ml) were injected; for the venusYFP group
and the SV2 group, 2 μl of AAV8-venus (1•1012 viral gen-
ome/ml) and 2 μl of AAV8-SV2 were injected, respectively.
At the end of injection the needle remained in place for
5 minutes before gradual removal.
For in vivo imaging, C57 mice were anesthetized with
2% isoflorane and placed in a stereotaxic frame above a
heated blanket. The surgical site was sterilized with
betadine and isopropanol prior to conducting a 1 cm in-
cision along the midline. The scalp was incised and an
injection targeting layers 2–3 of the cortex was preformed
at coordinates AP −1, ML −1 and DV −0.7 with bregma
as a point of reference. A total volume of 2 μl (1 μl V1S +
1 μl SV2) was injected at a rate of 0.1 μl/min using a
microinjection pump and 10 μl Hamilton syringe with a
33-gauge needle. After 4 weeks a cranial window was in-
stalled as described previously [22]. All studies were
performed with the approval of the MassachusettsGeneral Hospital Animal Care and Use Committee and in
compliance with the National Institute of Health guide-
lines for the use of experimental animals.
Tissue processing
At 8 weeks post-injection, rats were deeply anesthetized
and transcardially perfused with 0.01 M phosphate
buffered saline (PBS, pH7.4, Sigma) followed by 4% para-
formaldehyde in PBS. Brains were post-fixed for 24–
72 hours and transferred to a solution of 30% sucrose in
PBS. Frozen brain were sectioned at 40 μm on a sliding
microtome and kept in a cryoprotectant solution (30%
sucrose, 30% ethylene glycol in PBS).
Immunostaining
Free-floating coronal sections were washed overnight in
PBS to remove cryoprotectant. Unless otherwise stated,
all steps were performed at room temperature with three
10 min washes in PBS-TX (0.3% triton X-100) between
each step. For diaminobenzidine (DAB) staining sections
were treated with 10% methanol and 3% H2O2 to inhibit
endogenous peroxidases, permeabilized in PBS-TX for
30 min and blocked in 5% NGS in PBS-TX for 30 min.
Sections were incubated with primary antibody rabbit
anti- TH (1:10 K, Millipore) or mouse anti α-syn (4B12
1:1000, Signet) over night at 4°C followed by secondary
goat anti rabbit- biotin or goat anti mouse-biotin (1:200
Jackson ImmunoResearch) for 1 hour at room tem-
perature and either avidin-biotin (Vectastain kit) or
streptavidin-alexa555 for 1 hour at room temperature.
Sections were incubated with DAB (Vector laboratories) to
visualize TH positive cells, rinsed in PBS, mounted on
superfrost slides (Fisher scientific) and coverslipped
(Permount, Sigma). For immunofluorescence, sections were
mounted onto superfrost, coverslipped with vectashield
(Vector laboratories) and kept at 4°C.
Proteinase K
Striatal coronal sections were mounted onto slides and
dried prior to rehydration in 0.5 M Tris buffered saline
containing 0.05% Tween-20 (TBST, pH7.4). Digestion of
mounted sections was carried out with 50 μg/ml pro-
teinase K at 55°C for 120 min. Sections were post fixed
with 4% PFA for 30 min at room temperature and
washed with TBST. Immunostaining of treated and non-
treated sections with mouse anti α-syn clone 4B12 was
conducted as described in the immunostaining section.
Microscopy and stereology
Fluorescence images were obtained on either a Zeiss
LSM510 META confocal microscope with X20 magnifi-
cation or a Zeiss Axio observer inverted microscope, X5
magnification. In vivo images of anesthetized mice were
obtained using a Bio-Rad 1024ES multiphoton
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microscope. Dopaminergic neuron analysis was
performed with an Olympus BX51 microscope. At least
8 coronal sections per animal throughout the SN were
analyzed to determine tyrosine hydroxylase cell loss by
conducting unbiased stereology cell counting according
to the optical fractionator principle [39] using the Olym-
pus CAST stereology software. At least 4 coronal sec-
tions for GFAP and 3 for Iba1 per animal, were analyzed
to determine the level of protein expression throughout
the striatum using high definition images obtained by
automated collection and stitching of X5 images using
the MetaMorph software (MetaMorph). The striatum,
ipsilateral and contralateral, was outlined and the mean
intensity in the region of interest was determined using
FIJI (NIH).
Statistics
GFAP and Iba1 expression was analyzed using Mann
Whitney test. Data is expressed as group median with
interquartile range. TH cell count was analyzed using
one tailed t-test. Data is expressed as group mean ± SD.
Statistical analysis was performed using GraphPad Prism
software.
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